

Synthesis and evaluation of antimicrobial activity of some new 3-(pyrrol-4-yl)acrylamide derivatives

Sergiy Kemsykyi^a, Mariana Fedoriv^{a,b}, Alina Palamar^c, Alina Grozav^{c*}, Vitaliy Chornous^c, Roman Kutsyk^b, Viktor Dorokhov^a, and Mykhailo Vovk^a

^aInstitute of Organic Chemistry of National Academy of Sciences of Ukraine, 5 Murmanska St., Kyiv, Ukraine

^bIvano-Frankivsk National Medical University, Halyts'ka St., Ivano-Frankivsk, Ukraine

^cBukovinian State Medical University, 2 Teatral'na Sq., Chernivtsi, Ukraine

CHRONICLE

Article history:

Received December 20, 2022

Received in revised form

January 28, 2023

Accepted March 10, 2023

Available online

March 13, 2023

Keywords:

5-Chloro-4-formylpyrrole

Knoevenagel reaction

3-(Pyrrol-4-yl)acrylamides

Antibacterial and antifungal activity

ABSTRACT

A series of new derivatives of 3-(pyrrol-4-yl)acrylamides **3a-l** with the pyrrole nucleus functionalized by chlorine atoms and ester group, have been synthesized by simple preparative methods from the available esters of 5-chloro-4-formylpyrrol-3-carboxylic acids **1a-e**. At first, 3-(pyrrol-4-yl)acrylic acids **2a-e** were synthesized by the Knoevenagel's reaction between malonic acid and the esters **1a-e**. Then the target compounds were obtained with a high yield in the reactions between chloroanhydrides of the synthesized acrylic acids and aromatic or aliphatic amines in the boiling benzene. The structure of all obtained compounds was confirmed by elemental analysis, IR, ¹H-NMR, and ¹³C-NMR spectroscopy, and additionally checked by the mass-spectrometry. Then the antimicrobial activity of all amides was tested *in vitro* on some gram-positive and gram-negative bacteria and fungi. It has been found that the gram-negative bacteria are resistant against the synthesized chemicals, while the gram-positive bacteria are sensitive to the amides **3c, e, f, g, i**. The highest activity against *Staphylococcus aureus* MR and *Staphylococcus epidermidis* MS was registered for the amide **3f**, and the retardation area diameter for this amide was greater than that for the control drugs.

© 2023 by the authors; licensee Growing Science, Canada.

1. Introduction

It is reported by WHS that a microbial resistance is one of the most challenging global threats to public health.¹ As a bacterial multi-resistance grows in various strains of gram-positive bacteria including the methicillin-resistant bacteria of the genus *Staphylococcus*, penicillin-resistant bacteria of the genus *Streptococcus*, and vancomycin-resistant *Enterococcus*,² the search for new effective antibacterial compounds becomes more and more topical. Besides such bacterial resistance, a fungal resistance also grows rapidly in many fungal pathogens, which brings new challenges for the health protection system.³ That is why, the construction of new anti-germ compounds, including those based on the heterocyclic molecules, keeps its topicality.

In the framework of the development of the highly efficient antimicrobial agents based on the polyfunctional and condensed pyrrole systems,⁴⁻⁶ this work represents the results of the investigation of some previously unknown amides of acrylic acid consisting a functionalized pyrrole fragment in the alkenylic part of the molecule. Even though the information related to this type of compounds is very scarce,⁷⁻⁹ special attention should be given to the recently published method of synthesis of such compounds that is based on the Ru(0)-catalyzed alkenization in the β-position of α-aminofunctionalized pyrroles¹⁰. Amides of 3-pyrrolylsubstituted acrylic acids are used in this method because they are in fact heteroanalogues of cinnamic acid amides known as active antimicrobial agents.¹¹⁻¹⁵ On the other hand, another type of benzoanalogues of the above unknown amides, derivatives of indolyl-3-acrylamides are known as pharmaceutically active chemicals. For instance,

* Corresponding author.

E-mail address hrozav.alina@bsmu.edu.ua (A. Grozav)

they can be used as the inhibitors of hepatitis C virus (HCV),¹⁶ human immune deficit virus (HIV),¹⁷ human deacylglycerol acyltransferase-2 (DGAT-2),¹⁸ and also as antiproliferation agents.^{19,20}

Since the pyrrole scaffold is important for the construction of various bioactive compounds,²¹⁻²³ the synthetically potent formyl and ester groups, and a chlorine atom as a pharmacophoric substitute should be present in the basic pyrrole substrates to be transformed into further pharmaceutical agents. It should be emphasized that the pharmaceutical effectiveness of organic compounds increases if they consist of chlorine.^{24,25} This effect is based on the improved absorption,²⁶ and allocation of the biotargets in the hydrophobic ‘pockets’²⁷. A series of esters of 5-chloro-4-formylpyrrol-3-carboxylic acids **1a-e** recently synthesized by us²⁸ and the authors of²⁹ completely satisfies the above requirements and that is why these compounds were used for the synthesis of the target pyrrolacrylamides. As shown before, the compounds of class **1** can be effectively used as synthetic units in construction of some pyrrol[2,3-*b*]quinoline³⁰ and pyrrol[3,4-*b*:3',4'-*d*]pyridine³¹ systems.

2. Results and Discussion

2.1 Synthesis and spectra characteristics

We have developed a preparative simple method of synthesis in which the esters of 5-chloro-4-formylpyrrol-3-carboxylic acids **1a-e** are transformed in the corresponding acrylamides (**Fig. 1**). At the first stage, the compounds **1a-e** interact with malonic acid by the Knoevenagel reaction and form the respective 3-(pyrrol-4-yl)acrylic acids **2a-e** which yields 86-93 %. Their IR spectra reveal the medium intensity absorbance bands corresponding to the groups C=C (1639-1645 cm⁻¹), carboxylic C=O (1700-1710 cm⁻¹), carboxylic C=O (1720-1730 cm⁻¹), and wider absorbance bands of the carboxylic O-H (2524-2832 cm⁻¹). The peaks related to the pyrrole-like derivatives, the carboxylic group singlets at 12.15-12.25 ppm, and the doublets of C²H= and C³H= protons in the ranges 6.38-6.50 and 7.98-8.04 ppm respectively were found in the ¹H-NMR spectra of the above compounds recorded for *J* = 16.0 Hz. It is a proof of the *trans*-configuration of a pyrrole fragment and a carboxylic group in the regard of a double bond.

At the second stage, chloroanhydrides of the acids **2a-e** were synthesized by a 4 h long boiling of the respective acids in a benzene solution of excessive thionyl chloride. Further, the raw uncleaned chloroanhydrides reacted with aromatic or aliphatic amines in a boiling acetonitrile solution of triethylamine. This process lasted during 3 h. As a result the amides **3a-l** of 3-(pyrrol-4-yl)acrylic acid were obtained with yields 72-94% (**Table 1**). Even though a pyrrole fragment of the intermediate chloroanhydrides consists of an electrophilic ester group, the reactions with substituted anilines and more basic aliphatic amines remain regioselective and involve only chlorocarbonyl function.




Fig. 1. Synthesis of new derivatives of 3-(pyrrol-4-yl)acrylamides

Table 1. Structure of synthesized compounds

Compound	Structure	Compound	Structure
3 a		3g	
3 b		3h	
3c		3 i	
3d		3j	
3e		3k	
3f		3l	

Structural composition of the amides **3a-l** was confirmed by their spectral characteristics. For instance, the absorption bands of the valent asymmetric oscillations of bonds C=C ($1634\text{-}1649\text{ cm}^{-1}$), amide C=O ($1665\text{-}1676\text{ cm}^{-1}$), and ester C=O ($1720\text{-}1728\text{ cm}^{-1}$) were found in their IR spectra. The NH absorption band of monosubstituted amides **3a, b, d, e, h-k** was registered at $3240\text{-}3254\text{ cm}^{-1}$. The doublet peaks of C²H= and C³H= protons were registered in the ¹H-NMR spectra of synthesized compounds **3a-l** at 6.73-7.19 and 7.94-8.23 ppm for $J = 16.0$ Hz. Thus, the introduction of aromatic amines in the structure of compounds **3** does not cause any changes in the shift of the C²H= protons, and leads to a weak-field shift of the C²H= protons on average by 0.3 ppm on average as compared to acids **2**. On the contrary, the similar effect caused by the introduction of cycloalkylamino groups (compounds **3c, f, g**) is more significant, and it causes a shift of the abovementioned protons towards a weaker field by 0.6-0.7 ppm.

2.2 Antimicrobial activity

The 10 µg/ml solutions of synthesized amides **3a-l** have been evaluated for antimicrobial activity on some archive strains and clinical isolates of antibiotic-sensitive (MS) and antibiotic-resistant (MR) microorganisms including gram-positive *Staphylococcus aureus* MR and MS, *Staphylococcus haemolyticus* MR, *Staphylococcus epidermidis* MS, *Bacillus subtilis*,

Streptococcus pyogenes, *Streptococcus oralis*, *Streptococcus gordonii*; gram-negative *Klebsiella pneumoniae* and *Escherichia coli* ATCC 35218, and fungi *Candida albicans* and *Candida tropicalis*. Chlorhexidine³² and Decamethoxin (Dekasan)³³ were used as the control antiseptic and disinfection agents revealing activity against bacteria and fungi.

It was found that the gram-negative bacteria *Klebsiella pneumoniae* and *Escherichia coli* are not sensitive to the studied amides **3a-l**. In contrary, the gram-positive bacteria were found sensitive to the amides **3c, e, f, g, i** (Table 2). In particular, *Staphylococcus aureus* MS, *Streptococcus pyogenes* and *Streptococcus gordonii* are sensitive to the amides **3g** and **3f**, *Staphylococcus aureus* MR, *Staphylococcus haemolyticus* MR and *Staphylococcus epidermidis* MS – to the amides **3c, f, g**, *Bacillus subtilis* – to the amides **3f, g, i**, and *Streptococcus oralis* – to the amides **3e, f, g**. Some antifungal activity has been found in the amides **3c, f, g**, in particular, the amide **3c** retards the proliferation of *Candida albicans*, and the compounds **3c, f, g** – *Candida tropicalis*.

Basing on these results, we can emphasize the antistaphylococcus activity of the amide **3f** against *Staphylococcus aureus* MR and *Staphylococcus epidermidis* MS, for which the retardation area diameter was 14.65 mm, which is greater than that for the control agents. Such a notable antibacterial effect can be caused by the strong electron-donating dimethylamino group of the amide fragment, which increases a lipophilicity of the molecule³⁴. Taking into account the natural resistance of staphylococcus bacteria against many drugs, a deeper study of the amide **3f** will be taken.

Table 2. Antimicrobial activity of the synthesized compounds

Name of bacteria (fungus)	3c	3e	3f	3g	3i	C ¹	C ²
<i>Staphylococcus aureus</i> MS	-	-	7.14 ±0.25	8.80 ±1.10	-	11.90 ±0.19	14.29 ±0.21
<i>Staphylococcus aureus</i> MR	11.64 ±0.63	-	14.56 ±0.20	14.00 ±0.46	-	12.00 ±1.17	13.65 ±0.25
<i>Staphylococcus haemolyticus</i> MR	4.92 ±0.36	-	10.21 ±0.77	8.35 ±0.47	-	13.50 ±0.45	15.81 ±0.77
<i>Staphylococcus epidermidis</i> MS	6.64 ±0.43	-	14.65 ±0.35	13.16 ±0.22	-	14.50 ±0.17	13.87 ±1.10
<i>Bacillus subtilis</i>	-	-	12.11 ±0.30	11.65 ±0.36	12.68 ±1.33	20,96 ±0,68	23.08 ±0.42
<i>Streptococcus pyogenes</i>	-	-	6.46 ±0.19	5.42 ±0.31	-	11.96 ±0,86	14.25 ±0.78
<i>Streptococcus oralis</i>	-	13.3 ±0.73	12.73 ±1.16	13.39 ±0.88	-	20.25 ±0.23	16.39 ±0.64
<i>Streptococcus gordonii</i>	-	-	6.66 ±0.55	6.73 ±0.95	-	16.23 ±0.56	15.22 ±0.59
<i>Candida albicans</i>	5.30 ±0.52	-	-	-	-	11.71 ±0.39	10.20 ±0.36
<i>Candida tropicalis</i>	5.71 ±0.66	-	5.32 ±0.28	5.73 ±0.66	-	6.38 ±0.17	11.69 ±0.36

C¹ – 0.05% solution of chlorhexidine (by PJSC Pharmaceutical factory «Viola»)

C² – 0.02% solution of Dekasan (by LLC «YuriyaPharm»)

3. Conclusions

It can be concluded that an efficient method of synthesis of new antimicrobial active 3-(pyrrol-4-yl)acrylamides has been developed. These products consist of biophoric chlorine atoms and an easily modifiable ester group in the pyrrole cycle. This method is very promising as it involves readily available reactants, easy procedures of synthesis, and ensures high yields of intermediate and final compounds. Structural composition of the synthesized products was confirmed by IR-, ¹H (¹³C)-NMR-spectroscopy, mass spectrometry, and elemental analysis. As seen from the evaluation of antimicrobial properties of the synthesized amides, the compounds **3c, e, f, g, i** are highly efficient against gram-positive bacteria. Special attention should be given to the compound **3f** because its activity against *Staphylococcus aureus* MR and *Staphylococcus epidermidis* MS is greater than that of the control drugs. As seen from the antimicrobial activity investigation, the obtained 3-(pyrrol-4-yl)acrylamides deserve further study as prospective antigerm agents.

4. Experimental

4.1. Materials and Methods

All chemicals were of analytical grade and commercially available. When performing the synthetic part of the work, the reagents of the company Merck (Germany) and Sigma-Aldrich (USA) were used. All reagents and solvents were used

without further purification and drying. All the melting points were determined in an open capillary and left uncorrected. IR spectra were recorded on Bruker Vertex 70 FT-IR spectrometer for samples in KBr pellets. ¹H-NMR spectra were acquired in pulse Fourier transform mode on a Varian VXR-400 spectrometer (400 MHz) in DMSO-d₆ (compounds **2 a-e**) or CDCl₃ (compounds **3 a-l**), while ¹³C-NMR spectra of all compounds were recorded on a Bruker Avance DRX-500 spectrometer. The solvent signal (DMSO-d₆: 2.49 ppm for ¹H nuclei, 39.5 ppm for ¹³C nuclei; CDCl₃: 7.26 ppm for ¹H nuclei) served as the internal standard. Mass spectra were recorded on an Agilent LC/MSD SL mass spectrometer; column: Zorbax SB-C18, 4.6 × 15 mm, 1.8 μm (PN 82 (c)75-932); DMSO solvent, atmospheric pressure electrospray ionization. Elemental analysis was performed on a Perkin Elmer 2400 CHN-analyzer. Melting points were determined on a Kofler bench and left uncorrected.

4.2. General procedure

General procedure for the synthesis of 3-[2-chloro-4-(ethoxycarbonyl)-1H-pyrrol-3-yl]acrylic acids (2a-e). A solution of sodium acetate (4.08 g, 30 mmol) in 5 ml of ethanol was added to a suspension of ethyl 5-chloro-4-formylpyrrol-3-carboxylate **1a-e** (10 mmol) and malonic acid (1.04 g, 10 mmol) in 25 ml of pyridine. The mixture was boiled for 24 h, then cooled and poured into 100 mL of a 1N HCl. The sediment was filtered, washed by 50 mL of water, dried and recrystallized from a 70 % aqueous solution of ethanol.

General procedure for the synthesis of ethyl 1-R¹,2-R²-5-chloro-4-[[3-(4-R³R⁴-amino)]-3-oxoprop-1-enyl]-1H-pyrrole-3-carboxylates (3a-l). 0.89 g (7.5 mmol) of thionylchloride were added to a suspension of 3-[2-chloro-4-(ethoxycarbonyl)-1H-pyrrol-3-yl]acrylic acid **2a-e** (5 mmol) in 25 mL of benzene and boiled for 4 h. After evaporation of the solvent, the dry residue was dissolved in 20 mL of acetonitrile. Then 5 mmol of the corresponding amine and 0.51 g (5 mmol) of triethylamine were added to the solution. The mixture was boiled for 3 h, cooled and filtered. Acetonitrile was evaporated and the sediment was recrystallized from a 70 % aqueous solution of ethanol.

4.3 Physical and Spectral Data

4.3.1 3-[2-Chloro-4-(ethoxycarbonyl)-1,5-dimethyl-1-propyl-1H-pyrrol-3-yl]acrylic acid (2a). Yield 86 % (2.34 g), white solid, m. p. 169-171 °C; IR (KBr, cm⁻¹): 1637(C=C), 1705(C=O), 1722(C=O), 2524-2808 (OH); ¹H-NMR (500 MHz, DMSO-d₆) δ (ppm): 1.27 (3H, t, *J* = 7.2 Hz, OCH₂CH₃), 2.44 (3H, s, CH₃), 3.50 (3H, s, NCH₃), 4.21 (2H, k, *J* = 7.2 Hz, OCH₂CH₃), 6.38 (1H, d, *J* = 16.0 Hz, CH), 7.98 (1H, d, *J* = 16.0 Hz, CH), 12.15 (1H, s, CO₂H). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 12.3, 14.5, 31.4, 60.0, 110.3, 114.1, 117.9, 118.0, 136.1, 136.4, 164.2, 168.6. MS, *m/z* (*I*_{OTH}, %): 272 [M-H]⁺ (100). Anal. Calcd. for C₁₂H₁₄ClNO₄ (%): C, 53.05; H, 5.19; N, 5.16. Found: C, 49.92; H, 5.31; N, 5.29.

4.3.2 3-[2-Chloro-4-(ethoxycarbonyl)-5-methyl-1-propyl-1H-pyrrol-3-yl]acrylic acid (2b). Yield 92% (2.86 g), white solid, m. p. 154-155 °C; IR (KBr, cm⁻¹): 1639(C=C), 1705(C=O), 1724(C=O), 2536-2810(OH); ¹H-NMR (500 MHz, DMSO-d₆) δ (ppm): 0.86 (3H, t, *J* = 7.2 Hz, NCH₂CH₂CH₃), 1.28 (3H, t, *J* = 7.2 Hz, OCH₂CH₃), 1.47-1.68 (2H, m, NCH₂CH₂CH₃), 2.46 (3H, s, CH₃), 3.92 (2H, t, *J* = 7.2 Hz, NCH₂), 4.20 (2H, k, *J* = 7.2 Hz, OCH₂CH₃), 6.40 (1H, d, *J* = 16.0 Hz, CH), 7.98 (1H, d, *J* = 16.0 Hz, CH), 12.19 (1H, s, CO₂H). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 11.2, 12.1, 14.6, 23.0, 45.8, 60.1, 110.7, 114.4, 117.4, 118.2, 136.1, 136.8, 164.2, 168.5. MS, *m/z* (*I*_{OTH}, %): 310 [M-H]⁺ (100). Anal. Calcd. for C₁₄H₁₈ClNO₄ (%): C, 56.10; H, 6.05; N, 4.67. Found: C, 56.23; H, 5.98; N, 4.54.

4.3.3 3-[1-Butyl-2-chloro-4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-3-yl]acrylic acid (2c). Yield 93% (2.92 g), white solid, m. p. 147-148 °C; IR (KBr, cm⁻¹): 1642(C=C), 1708(C=O), 1727(C=O), 2540-2812(OH); ¹H-NMR (500 MHz, DMSO-d₆) δ (ppm): 0.89 (3H, t, *J* = 7.2 Hz, N(CH₂)₃CH₃), 1.21-1.39 (5H, m, CH₂ + OCH₂CH₃), 1.49-1.61 (2H, m, CH₂), 2.46 (3H, s, CH₃), 3.94 (2H, t, *J* = 7.2 Hz, NCH₂), 4.20 (2H, k, *J* = 7.2 Hz, OCH₂CH₃), 6.40 (1H, d, *J* = 16.0 Hz, CH), 7.98 (1H, d, *J* = 16.0 Hz, CH), 12.20 (1H, s, CO₂H). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 12.1, 13.9, 14.6, 19.7, 31.7, 44.2, 60.1, 110.1, 114.4, 117.4, 118.2, 136.1, 136.7, 164.2, 168.4. MS, *m/z* (*I*_{OTH}, %): 314 [M-H]⁺ (100). Anal. Calcd. for C₁₅H₂₀ClNO₄ (%): C, 57.42; H, 6.42; N, 4.46. Found: C, 57.29; H, 6.49; N, 4.50.

4.3.4 3-[1-Benzyl-2-chloro-4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-3-yl]acrylic acid (2d). Yield 88% (2.80 g), white solid, m. p. 188-190 °C; IR (KBr, cm⁻¹): 1645(C=C), 1706(C=O), 1725(C=O), 2531-2823(OH); ¹H-NMR (500 MHz, DMSO-d₆) δ (ppm): 1.28 (3H, t, *J* = 7.2 Hz, OCH₂CH₃), 2.41 (3H, s, CH₃), 4.22 (2H, k, *J* = 7.2 Hz, OCH₂CH₃), 5.30 (2H, s, CH₂Ph), 6.43 (1H, d, *J* = 16.0 Hz, CH), 7.01 (2H, d, *J* = 7.2 Hz, Ph), 7.23-7.40 (3H, m, Ph), 8.04 (1H, d, *J* = 16.0 Hz, CH), 12.25 (1H, s, CO₂H). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 12.3, 14.5, 47.4, 60.2, 111.2, 114.7, 118.0, 118.7, 126.3 (2C), 128.0, 129.3 (2C), 136.0, 136.3, 137.3, 164.2, 168.4. MS, *m/z* (*I*_{OTH}, %): 318 [M-H]⁺ (100). Anal. Calcd. for C₁₈H₁₈ClNO₄ (%): C, 62.16; H, 5.22; N, 4.03. Found: C, 62.33; H, 5.17; N, 3.94.

4.3.5 3-[2-Chloro-4-(ethoxycarbonyl)-5-phenyl-1-propyl-1H-pyrrol-3-yl]acrylic acid (2e). Yield 85% (3.08 g), white solid, m. p. 162-164 °C; IR (KBr, cm⁻¹): 1639(C=C), 1710(C=O), 1730(C=O), 2525-2832(OH); ¹H-NMR (500 MHz, DMSO-d₆) δ (ppm): 0.63 (3H, t, *J* = 7.2 Hz, NCH₂CH₂CH₃), 0.78 (3H, t, *J* = 7.2 Hz, OCH₂CH₃), 1.37-1.54 (2H, m, NCH₂CH₂CH₃), 3.70 (3H, t, *J* = 7.2 Hz, NCH₂), 3.89 (2H, k, *J* = 7.2 Hz, OCH₂CH₃), 6.50 (1H, d, *J* = 16.0 Hz, CH), 7.31-7.48 (5H, m, Ph), 7.98 (1H, d, *J* = 16.0 Hz, CH), 12.25 (1H, s, CO₂H). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 11.1, 13.8, 23.2, 46.7,

59.8, 112.3, 114.9, 118.8, 118.9, 126.5 (2C), 129.3, 130.8 (2C), 131.4, 135.3, 139.1, 163.6, 168.4. MS, m/z (I_{orb} , %): 362 [M-H]⁺ (100). Anal. Calcd. for C₁₉H₂₀ClNO₄ (%): C, 63.07; H, 5.57; N, 3.81. Found: C, 63.22; H, 5.63; N, 3.69.

4.3.6 Ethyl 5-choro-4-[3-[(4-chlorophenyl)amino]-3-oxoprop-1-enyl]-1,2-dimethyl-1H-pyrrole-3-carboxylate (3a). Yield 83% (1.59 g), white solid, m. p. 197-199 °C; IR (KBr, sm⁻¹): 1638(C=C), 1665(C=O), 1720(C=O), 3248(N-H); ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 1.38 (3H, t, $J = 7.2$ Hz, OCH₂CH₃), 2.50 (3H, s, CH₃), 3.50 (3H, s, NCH₃), 4.30 (2H, k, $J = 7.2$ Hz, OCH₂CH₃), 6.73 (1H, d, $J = 16.0$ Hz, CH), 7.24 (2H, d, $J = 8.4$ Hz, Ar-H), 7.57 (2H, d, $J = 8.4$ Hz, Ar-H), 7.20 (1H, t, $J = 8.4$ Hz, NH), 8.04 (1H, d, $J = 16.0$ Hz, CH). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 12.2, 14.4, 31.0, 60.2, 111.1, 114.9, 118.2, 120.4, 121.0, 128.6, 128.7 (2C), 128.9 (2C), 133.8, 136.6, 137.1, 164.8. MS, m/z (I_{orb} , %): 382 [M-H]⁺ (100). Anal. Calcd. for C₁₈H₁₈Cl₂N₂O₃ (%): C, 56.71; H, 4.76; N, 7.35. Found: C, 56.65; H, 4.82; N, 7.46.

4.3.7 Ethyl 5-choro-4-[3-[(4-methylphenyl)amino]-3-oxoprop-1-enyl]-1,2-dimethyl-1H-pyrrole-3-carboxylate (3b). Yield 81% (1.46 g), white solid, m. p. 176-178 °C; IR (KBr, sm⁻¹): 1642(C=C), 1670(C=O), 1725(C=O), 3243(N-H); ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 1.40 (3H, t, $J = 7.2$ Hz, OCH₂CH₃), 2.32 (3H, s, CH₃), 2.52 (3H, s, CH₃), 3.52 (3H, s, NCH₃), 4.32 (2H, k, $J = 7.2$ Hz, OCH₂CH₃), 6.74 (1H, d, $J = 16.0$ Hz, CH), 7.12 (2H, d, $J = 8$ Hz, Ar-H), 7.47-7.55 (3H, m, Ar-H + NH), 8.09 (1H, d, $J = 16.0$ Hz, CH). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 11.6, 14.0, 20.4, 30.4, 59.6, 110.7, 114.8, 117.0, 119.1, 120.9, 127.9 (2C), 128.1 (2C), 132.2, 132.9, 135.1, 136.2, 164.4. MS, m/z (I_{orb} , %): 361 [M-H]⁺ (100). Anal. Calcd. for C₁₉H₂₁ClN₂O₃ (%): C, 63.24; H, 5.87; N, 7.76. Found: C, 63.39; H, 5.92; N, 7.63

4.3.8 Ethyl 5-choro-2-methyl-4-[3-morpholin-4-yl-3-oxoprop-1-enyl]-1-propyl-1H-pyrrole-3-carboxylate (3c). Yield 77% (1.42 g), white solid, m. p. 112-113 °C; IR (KBr, sm⁻¹): 1642(C=C), 1670(C=O), 1725(C=O); ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 0.93 (3H, t, $J = 7.2$ Hz, NCH₂CH₂CH₃), 1.36 (3H, t, $J = 7.2$ Hz, OCH₂CH₃), 1.62-1.73 (2H, m, NCH₂CH₂CH₃), 2.50 (3H, s, CH₃), 3.59-3.81 (8H, m, morpholin), 4.32 (2H, k, $J = 7.2$ Hz, OCH₂CH₃), 6.99 (1H, d, $J = 16.0$ Hz, CH), 7.98 (1H, d, $J = 16.0$ Hz, CH). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 11.0, 11.9, 14.4, 23.2, 43.4 (2C), 45.7, 60.0, 66.9 (2C), 111.3, 115.5, 116.6, 117.0, 128.7, 136.0, 164.9, 166.6. MS, m/z (I_{orb} , %): 369 [M-H]⁺ (100). Anal. Calcd. for C₁₈H₂₅ClN₂O₄ (%): C, 58.61; H, 6.83; N, 7.59. Found: C, 58.73; H, 6.76; N, 7.41

4.3.9 Ethyl 5-choro-4-[3-[(4-chlorophenyl)amino]-3-oxoprop-1-enyl]-2-methyl-1-propyl-1H-pyrrole-3-carboxylate (3d). Yield 84% (1.72 g), white solid, m. p. 158-160 °C; IR (KBr, sm⁻¹): 1646(C=C), 1673(C=O), 1728(C=O), 3250(N-H); ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 0.96 (3H, t, $J = 7.2$ Hz, NCH₂CH₂CH₃), 1.39 (3H, t, $J = 7.2$ Hz, OCH₂CH₃), 1.61-1.74 (2H, m, NCH₂CH₂CH₃), 2.52 (3H, s, CH₃), 3.87 (2H, t, $J = 7.2$ Hz, NCH₂CH₂CH₃), 4.31 (2H, k, $J = 7.2$ Hz, OCH₂CH₃), 6.77 (1H, d, $J = 16.0$ Hz, CH), 7.25 (2H, d, $J = 8.4$ Hz, Ar-H), 7.59 (2H, d, $J = 8.4$ Hz, Ar-H), 7.83 (1H, t, $J = 5.4$ Hz, NH), 8.10 (1H, d, $J = 16.0$ Hz, CH). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 10.6, 11.6, 14.0, 22.8, 45.4, 59.7, 111.4, 114.6, 117.3, 119.8, 120.6, 128.2 (2C), 128.5 (2C), 133.6, 133.7, 135.7, 136.6, 164.6. MS, m/z (I_{orb} , %): 410 [M-H]⁺ (100). Anal. Calcd. for C₂₀H₂₂Cl₂N₂O₃ (%): C, 58.69; H, 5.42; N, 6.84. Found: C, 58.71; H, 5.37; N, 6.78 .

4.3.10 Ethyl 4-[3-[(4-bromophenyl)amino]-3-oxoprop-1-enyl]-5-choro-2-methyl-1-propyl-1H-pyrrole-3-carboxylate (3e). Yield 89% (2.02 g), white solid, m. p. 164-165 °C; IR (KBr, sm⁻¹): 1649(C=C), 1676(C=O), 1726(C=O), 3254(N-H); ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 0.97 (3H, t, $J = 7.2$ Hz, NCH₂CH₂CH₃), 1.40 (3H, t, $J = 7.2$ Hz, OCH₂CH₃), 1.63-1.77 (2H, m, NCH₂CH₂CH₃), 2.53 (3H, s, CH₃), 3.89 (2H, t, $J = 7.2$ Hz, NCH₂), 4.34 (2H, k, $J = 7.2$ Hz, OCH₂CH₃), 6.75 (1H, d, $J = 16.0$ Hz, CH), 7.41 (2H, d, $J = 8.4$ Hz, Ar-H), 7.54 (2H, d, $J = 8.4$ Hz, Ar-H), 7.63 (1H, t, $J = 5.4$ Hz, NH), 8.12 (1H, d, $J = 16.0$ Hz, CH). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 10.6, 11.6, 14.0, 22.8, 45.4, 59.7, 110.9, 114.6, 116.0, 117.3, 119.8, 121.0, 131.2 (2C), 131.6 (2C), 133.7, 135.7, 137.1, 164.4. MS, m/z (I_{orb} , %): 454 [M-H]⁺ (100). Anal. Calcd. for C₂₀H₂₂BrClN₂O₃ (%): C, 52.94; H, 4.89; N, 6.17. Found: C, 53.11; H, 4.81; N, 6.09

4.3.11 Ethyl 5-choro-4-[3-(dimethylamino)-3-oxoprop-1-enyl]-2-methyl-1-propyl-1H-pyrrole-3-carboxylate (3f). Yield 82% (1.64 g), white solid, m. p. 173-174 °C; IR (KBr, sm⁻¹): 1639(C=C), 1670(C=O), 1721(C=O); ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 0.73 (3H, t, $J = 7.2$ Hz, NCH₂CH₂CH₃), 0.96 (3H, t, $J = 7.2$ Hz, OCH₂CH₃), 1.49-1.30 (2H, m, NCH₂CH₂CH₃), 3.05 (3H, s, NCH₃), 3.15 (3H, s, NCH₃), 3.71 (2H, t, $J = 7.2$ Hz, NCH₂), 4.01 (2H, k, $J = 7.2$ Hz, OCH₂CH₃), 7.19 (1H, d, $J = 16.0$ Hz, CH), 7.21-7.29 (2H, m, Ph), 7.32-7.44 (3H, m, Ph), 7.94 (1H, d, $J = 16.0$ Hz, CH). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 10.9, 13.8, 23.6, 32.9, 35.9, 46.5, 59.9, 112.7, 116.2, 118.3, 118.6, 128.1 (2C), 128.7, 130.5 (2C), 131.7, 132.8, 138.6, 164.3, 167.6. MS, m/z (I_{orb} , %): 399 [M-H]⁺ (100). Anal. Calcd. for C₂₁H₂₅ClN₂O₃ (%): C, 64.86; H, 6.48; N, 7.20. Found: C, 64.79; H, 6.54; N, 7.33 .

4.3.12 Ethyl 5-choro-4-[3-oxo-3-pyrrolidin-1-ylprop-1-enyl]-2-phenyl-1-propyl-1H-pyrrole-3-carboxylate (3g). Yield 72% (1.48 g), white solid, m. p. 139-140 °C; IR (KBr, sm⁻¹): 1634 (C=C), 1669(C=O), 1720(C=O); ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 0.72 (3H, t, $J = 7.2$ Hz, NCH₂CH₂CH₃), 0.97 (3H, t, $J = 7.2$ Hz, OCH₂CH₃), 1.50-1.59 (2H, m, NCH₂CH₂CH₃), 1.81-1.99 (4H, m, 2CH₂pyrrolidin), 3.52-3.65 (4H, m, 2CH₂pyrrolidin), 3.70 (2H, t, $J = 7.2$ Hz, NCH₂), 4.03 (2H, k, $J = 7.2$ Hz, OCH₂CH₃), 7.03 (1H, d, $J = 16.0$ Hz, CH), 7.21-7.30 (2H, m, Ar-H), 7.35-7.43 (3H, m, Ar-H), 7.97 (1H, d, $J = 16.0$ Hz, CH). ¹³C-NMR (125.7 MHz, DMSO-d₆) δ (ppm): 10.9, 13.8, 23.5, 24.4, 26.1, 45.8, 46.4, 46.6, 59.9, 113.4, 116.2, 118.6, 119.8, 128.1 (2C), 128.7, 130.5 (2C), 131.7, 132.1, 138.6, 164.2, 165.6. MS, m/z (I_{orb} , %): 415 [M-H]⁺ (100). Anal. Calcd. for C₂₃H₂₇ClN₃O₃ (%): C, 66.58; H, 6.56; N, 6.75. Found: C, 66.43; H, 6.68; N, 6.86 .

4.3.13 Ethyl 1-butyl-5-choro-4-{3-[(4-chlorophenyl)amino]-3-oxoprop-1-enyl}-2-methyl-1H-pyrrole-3-carboxylate (3h). Yield 75% (1.54 g), white solid, m. p. 123-125 °C; IR (KBr, cm^{-1}): 1648(C=C), 1676(C=O), 1724(C=O), 3240(N-H); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm): 0.98 (3H, t, $J = 7.2$ Hz, $\text{N}(\text{CH}_2)_3\text{CH}_3$), 1.34-1.45 (5H, m, $\text{CH}_2 + \text{OCH}_2\text{CH}_3$), 1.61-1.69 (2H, m, CH_2), 2.52 (3H, s, CH_3), 3.91 (2H, t, $J = 7.2$ Hz, NCH_2), 4.31 (2H, k, $J = 7.2$ Hz, OCH_2CH_3), 6.73 (1H, d, $J = 16.0$ Hz, CH), 7.04 (2H, d, $J = 8.4$ Hz, Ar-H), 7.43 (1H, t, $J = 5.4$ Hz, NH), 7.58 (2H, d, $J = 8.4$ Hz, Ar-H), 8.23 (1H, d, $J = 16.0$ Hz, CH). $^{13}\text{C-NMR}$ (125.7 MHz, DMSO-d_6) δ (ppm): 12.1, 13.7, 14.5, 19.9, 31.9, 44.1, 60.1, 111.6, 115.2, 118.0, 120.1, 128.9, 128.9 (2C), 129.6 (2C), 134.0, 136.2, 136.7, 137.9, 164.7. MS, m/z (I_{rel} , %): 410 $[\text{M-H}]^+$ (100). Anal. Calcd. for $\text{C}_{21}\text{H}_{24}\text{Cl}_2\text{N}_2\text{O}_3$ (%): C, 59.58; H, 5.71; N, 6.62. Found: C, 59.71; H, 5.63; N, 6.50.

4.3.14 Ethyl 1-butyl-5-choro-2-methyl-4-{3-[(4-methylphenyl)amino]-3-oxoprop-1-enyl}-1H-pyrrole-3-carboxylate (3i). Yield 85% (1.71 g), white solid, m. p. 137-138 °C; IR (KBr, cm^{-1}): 1645(C=C), 1666(C=O), 1722(C=O), 3244(N-H); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm): 0.98 (3H, t, $J = 7.2$ Hz, $\text{N}(\text{CH}_2)_3\text{CH}_3$), 1.30-1.45 (5H, m, $\text{CH}_2 + \text{OCH}_2\text{CH}_3$), 1.61-1.68 (2H, m, CH_2), 2.23 (3H, s, CH_3), 2.53 (3H, s, CH_3), 3.92 (2H, t, $J = 7.2$ Hz, NCH_2), 4.33 (2H, k, $J = 7.2$ Hz, OCH_2CH_3), 6.73 (1H, d, $J = 16.0$ Hz, CH), 7.12 (2H, d, $J = 8.4$ Hz, Ar-H), 7.42-7.54 (3H, m, NH + Ar-H), 8.10 (1H, d, $J = 16.0$ Hz, CH). $^{13}\text{C-NMR}$ (125.7 MHz, DMSO-d_6) δ (ppm): 11.9, 13.7, 14.5, 19.9, 20.9, 32.0, 44.2, 60.1, 111.5, 115.0, 119.8, 120.9, 129.3 (2C), 129.6 (2C), 132.9, 132.1, 133.8, 134.2, 136.1, 164.9. MS, m/z (I_{rel} , %): 403 $[\text{M-H}]^+$ (100). Anal. Calcd. for $\text{C}_{22}\text{H}_{27}\text{ClN}_2\text{O}_3$ (%): C, 65.58; H, 6.75; N, 6.95. Found: C, 65.71; H, 6.69; N, 6.87.

4.3.15 Ethyl 1-butyl-5-choro-4-{3-[(4-methoxyphenyl)amino]-3-oxoprop-1-enyl}-2-methyl-1H-pyrrole-3-carboxylate (3j). Yield 89% (1.86 g), white solid, m. p. 132-134 °C; IR (KBr, cm^{-1}): 1644(C=C), 1665(C=O), 1727(C=O), 3251(N-H); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm): 0.98 (3H, t, $J = 7.2$ Hz, $\text{N}(\text{CH}_2)_3\text{CH}_3$), 1.33-1.44 (5H, m, $\text{CH}_2 + \text{OCH}_2\text{CH}_3$), 1.61-1.72 (2H, m, CH_2), 2.53 (3H, s, CH_3), 3.80 (3H, s, OCH_3), 3.92 (2H, t, $J = 7.2$ Hz, NCH_2), 4.33 (2H, k, $J = 7.2$ Hz, OCH_2CH_3), 6.74 (1H, d, $J = 16.0$ Hz, CH), 6.87 (2H, d, $J = 8.8$ Hz, Ar-H), 7.28 (1H, t, $J = 5.4$ Hz, NH), 7.53 (2H, d, $J = 8.8$ Hz, Ar-H), 8.09 (1H, d, $J = 16.0$ Hz, CH). $^{13}\text{C-NMR}$ (125.7 MHz, DMSO-d_6) δ (ppm): 11.9, 13.7, 14.5, 19.9, 32.0, 44.1, 55.5, 60.1, 111.4, 113.9 (2C), 114.1 (2C), 115.1, 117.3, 120.8, 121.5, 131.9, 133.3, 136.0, 156.9, 164.9. MS, m/z (I_{rel} , %): 419 $[\text{M-H}]^+$ (100). Anal. Calcd. for $\text{C}_{22}\text{H}_{27}\text{ClN}_2\text{O}_4$ (%): C, 63.08; H, 6.50; N, 6.99. Found: C, 63.23; H, 6.42; N, 6.88.

4.3.16 Ethyl 1-benzyl-5-choro-2-methyl-4-[3-(methylamino)-3-oxoprop-1-enyl]-1H-pyrrole-3-carboxylate (3k). Yield 94% (1.70 g), white solid, m. p. 171-173 °C; IR (KBr, cm^{-1}): 1640(C=C), 1667(C=O), 1724(C=O), 3254(N-H); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm): 1.36 (3H, t, $J = 7.2$ Hz, OCH_2CH_3), 2.41 (3H, s, CH_3), 2.89 (3H, d, $J = 4.8$ Hz, NCH_3), 4.33 (2H, k, $J = 7.2$ Hz, OCH_2CH_3), 5.31 (2H, s, CH_2Ph), 5.96 (1H, t, $J = 5.4$ Hz, NH), 6.76 (1H, d, $J = 16.0$ Hz, CH), 6.92-6.99 (2H, m, Ph), 7.25-7.32 (3H, m, Ph), 7.96 (1H, d, $J = 16.0$ Hz, CH). $^{13}\text{C-NMR}$ (125.7 MHz, DMSO-d_6) δ (ppm): 12.4, 14.4, 26.4, 47.4, 60.2, 111.8, 115.4, 117.2, 121.1, 125.9 (2C), 127.8, 129.0 (2C), 132.1, 135.5, 136.6, 164.8, 167.5. MS, m/z (I_{rel} , %): 361 $[\text{M-H}]^+$ (100). Anal. Calcd. for $\text{C}_{19}\text{H}_{21}\text{ClN}_2\text{O}_3$ (%): C, 63.24; H, 5.87; N, 7.76. Found: C, 63.38; H, 5.80; N, 7.64.

4.3.17 Ethyl 1-benzyl-5-choro-2-methyl-4-[3-morpholin-4-yl-3-oxoprop-1-enyl]-1H-pyrrole-3-carboxylate (3l). Yield 79% (1.65 g), white solid, m. p. 126-127 °C; IR (KBr, cm^{-1}): 1642(C=C), 1673(C=O), 1725(C=O); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm): 1.38 (3H, t, $J = 7.2$ Hz, OCH_2CH_3), 2.45 (3H, s, CH_3), 3.59-3.81 (8H, m, morpholin), 4.32 (2H, k, $J = 7.2$ Hz, OCH_2CH_3), 5.20 (2H, s, CH_2Ph), 6.93-7.09 (3H, m, CH + Ph), 7.27-7.36 (3H, m, Ph), 8.04 (1H, d, $J = 16.0$ Hz, CH). $^{13}\text{C-NMR}$ (125.7 MHz, DMSO-d_6) δ (ppm): 12.1, 14.4, 44.1 (2C), 47.4, 60.2, 66.9 (2C), 111.8, 115.9, 117.1, 117.4, 125.9 (2C), 127.8, 128.9 (2C), 134.4, 135.5, 136.7, 164.8, 166.6. MS, m/z (I_{rel} , %): 417 $[\text{M-H}]^+$ (100). Anal. Calcd. for $\text{C}_{22}\text{H}_{25}\text{ClN}_2\text{O}_4$ (%): C, 63.38; H, 6.04; N, 6.72. Found: C, 63.50; H, 6.11; N, 6.59.

4.4 Antimicrobial activity

A micromethod of diffusion into agar was used to evaluate an antimicrobial activity of the synthesized compounds. Nutritional agar was placed in the Petri bowls, and a series of 4.0 mm holes was made in it. Then the agar was uniformly populated with the standard suspensions of test-cultures with the concentration 1×10^7 CFU/mL. 20 μL of a 10 mg/mL solution of the studied compounds in a mixture DMSO/ethanol/ water (1:2:1) were added to each hole to evaluate their antimicrobial activity. To do that, a diameter of the bacterial colony's retardation area was measured 24 h after the addition of a compound by taking digital images of the colonies followed by their analysis performed by the software UTHSCSA ImageTool 3.0 (The University of Texas Health Science Center in San Antonio, ©1995-2002). Then the results were additionally processed using variational statistics methods. No retardation of the colony's growth was found in the control holes treated with a pure mixture DMSO/ethanol/ water (1:2:1).

In the above study, some archival strains and clinical isolates of the antibiotic sensitive and resistant microbes were involved. They were identified by their morphological, cultural features, and using the biochemical tests «STAPHYtest 16», «ENTEROtest 24», «STREPTOTest 16» (by Lachema, Czechia), test-systems VITEK 2 GP and VITEK 2 YST (by Biomerieux, France) on the analyzer VITEK 2 Compact.

References

- 1 World health organization (2022) Antimicrobial resistance. *World health statistics 2022: monitoring health for the SDGs, sustainable development goals*, 33-34.
- 2 Chen L., Yang D., Pan Z., Lai L., Liu J. Fang B., and Shi S. (2015) Synthesis and antimicrobial activity of the hybrid molecules between sulfonamides and active antimicrobial pleuromutilin derivative. *Chem. Biol. Drug. Des.*, 86 239-245.
- 3 Lee Y., Puumala E., Robbins N., Cowen L.E. (2021) Antifungal drug resistance: molecular mechanisms in *Candida albicans* and beyond. *Chem. Rev.*, 121 (6) 3390-3411.
- 4 Grozav A. M., Chornous V. O., Diichuk I. V., Kemsykyi S.V., Yakovychuk N.D., Fedoriv M.Z., and Vovk M.V. (2022) Synthesis and biological evaluation of *O*-acyloximes of 5-chloro-4-formyl-1*H*-pyrrol-3-carboxylates as antimicrobial agents. *Biopol. and Cell*, 38(1), 48-57.
- 5 Grozav A., Fedoriv M., Chornous V., Yakovychuk N., Kemsykyi S., and Vovk M. (2021) Synthesis and bioevaluation of 5-chloro-4-(1,3-oxazol-5-yl)-1*H*-pyrrole-3-carboxyamides as antimicrobial agents. *Biointerf. Res. Appl. Chem.*, 11 (3) 10595-10606.
- 6 Grozav A.M., Fedoriv M.Z., Chornous V.O., Yakovychuk N.D., Deineka S. Ye., and Kemsykyi S.V. (2019) Synthesis and antimicrobial activity of 5-aroxy-2,6-dihydro-1*H*-pyrrolo[3,4-*d*]pyridazine-1-ones. *J. Org. Pharm. Chem.*, 17 (2) 11-16.
- 7 Ducrocq C., Bisagni E., Lhoste J-M., Mispelter J., and Defaye J. (1976) Aza-indoles-III: Synthese de l'amino-4 aza-5 indole et du N-5 ribonucleoside correspondant (Iso-deaza-1 tubercidine). *Tetrahedron*, 32 (7) 773-778.
- 8 Ojika M., Shizuri Y., Niwa H., Yamada K., and Iwadare S. (1982) Structure and synthesis of reductiline, a novel metabolite from a variant of streptomyces orientalis. *Tetrahedron Lett.*, 23 (47) 4977-4980.
- 9 Wasley J.W.F. (1990) Certain pyrrolyl-substituted hydroxamic acid derivatives. **US Patent 4,960,787.**
- 10 Sala R., Kiala G., Veiros L.F., Broggin G., Poli G., and Oble J. (2022) Redox-neutral Ru(0)-natalyzed alkenylation of 2-carboxaldimine-heterocyclopentadienes. *J Org. Chem.*, 87 (7) 4640-4648.
- 11 Guzman J.D. (2014) Natural cinnamic acids, synthetic derivatives and hybrids with antimicrobial activity. *Molecules*, 19 (12) 19292-19349.
- 12 Ruwizhi N., and Aderibigbe B.A. (2020) Cinnamic acid derivatives and their biological efficacy. *Int. J. Mol. Sci*, 21 (16) 5712-5746.
- 13 Korošec B., Sova M., Turk S., Kraševc N., Novak M., Lah L., Stojan J., Podobnik B., Berne S., Zupanec N., Bunc M., Gobec S., and Komel R. (2014) Antifungal activity of cinnamic acid derivatives involves inhibition of benzoate 4-hydroxylase (CYP53). *J. Appl. Microbiol.*, 116 (4) 955-966.
- 14 Narasimhan B., Belsare D., Pharande D., Mourya V., and Dhake A. (2004) Esters, amides and substituted derivatives of cinnamic acid: synthesis, antimicrobial activity and QSAR investigations. *Eur. J. Med. Chem.*, 39 (10) 827-834.
- 15 Samwel S., Odalo J.O., Nkunya M.H.H., Joseph C.C., Koorbanally N.A. (2011) Toussaintines A–E: Antimicrobial indolidinoids, a cinnamoylhydrobenzofuranoid and a cinnamoylcyclohexenoid from *Toussaintia orientalis* leaves. *Phytochemistry*, 72 (14-15) 1826-1832.
- 16 Jin G., Lee S., Choi M., Son S., Kim G.-W., Oh J.-W., Lee C., and Lee K. (2014) Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors. *Eur. J. Med. Chem.*, 75 413-425.
- 17 Zhao Y., Chen C.-H., Morris-Natschke S.L., and Lee K.-H. (2021) Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors. *Eur. J. Med. Chem.*, 215 113287.
- 18 Lee K., Kim M., Lee B., Goo J., Kim J., Naik R., Seo J.H., Kim M.O., Byun Y., Song G.-Y., Lee H.S. and Choi Y. (2013) Discovery of indolyl acrylamide derivatives as human diacylglycerol acyltransferase-2 selective inhibitors. *Org. Biomol. Chem.*, 11 (5) 849-858.
- 19 Baytas N. S., Incelcer N., Yılmaz A., Olgac A., Menevse S., Banoglu E., Hamel E., Bortolozzi R., and Viola G. (2014) Synthesis, biological evaluation and molecular docking studies of trans-indole-3-acrylamide derivatives, a new class of tubulin polymerization inhibitors. *Bioorg. Med. Chem.*, 22 (12) 3096-3104.
- 20 Li Y., Wang Y., Xie N., Xu M., Qian P., Zhao Y., and Li S. (2015) Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors. *Eur. J. Med. Chem.*, 100 270-276.
21. Gholap S.S. (2016) Pyrrole: An emerging scaffold for construction of valuable therapeutic agents. *Eur. J. Med. Chem.*, 110 13-31.
- 22 Ahmad S., Alam O., Naim M.J., Shaquiquzzaman M., Alam M.M., and Iqbal M. (2018) Pyrrole: An insight into recent pharmacological advances with structure activity relationship. *Eur. J. Med. Chem.*, 157 527-651.
- 23 Singh N., Singh S., Kohli S., Singh A., Asiki H., Rathee G., Chandra R., and Anderson E.A. (2021) Recent progress in the total synthesis of pyrrole-containing natural products (2011–2020). *Org. Chem. Front.*, 8 5550-5573.
- 24 Buchini S., Buschiazzo A., and Withers S. G. (2008). A new generation of specific *Trypanosoma cruzi* trans-sialidase inhibitors. *Angew. Chem. Int. Ed.*, 47 (14) 2700-2703.
- 25 Leite A.C.L., Moreira D.R.M., Cardoso M.V.O., Hernandes M.Z., Pereira V.R.A., Silva R.O., Kiperstok A.C., Lima M.S., and Soares M.B.P. (2009) Synthesis, cruzain docking, and in vitro studies of aryl-4-oxothiazolyhydrazones against *Trypanosoma cruzi*. *ChemMedChem.*, 2 (9) 1339-1345.
- 26 Gerebtzoff G., Li-Blatter X., Fischer H, Frentzel A., and Seelig A. (2004) Halogenation of Drugs Enhances Membrane Binding and Permeation. *ChemBioChem.*, 5 676-684.
- 27 Siegal G., Ab E., and Schultz J. (2007) Integration of fragment screening and library design. *Drug Discov. Today*, 12

- (23-24) 1032-1039.
- 28 Grozav A. N., Fedoriv M. Z., Chornous V. A., Palamar A. A., Bratenko M. K., and Vovk M. V. (2019) Synthesis of thieno[2,3-*b*]pyrrole-2(4)-carboxylic and 2,4-dicarboxylic acids. *Chem. Heterocyclic Compd.*, 55 (4-5) 435-441.
 - 29 Metten B., Kostermans M., Van Boelen G., Smet M., and Dehaen W. (2006) Synthesis of 5-aryl-2-oxopyrrole derivatives as synthons for highly substituted pyrroles. *Tetrahedron*, 62 (25) 6018.
 - 30 Grozav A. N., Fedoriv M. Z., Chornous V.A., Kemsyky S.V., Polishchuk V.M., Shandura N.P., Rusanov E.B., and Vovk M.V. (2021) Cyclocondensation of 5-chloro-4-formylpyrrole-3-carboxylates with arylamines. Synthesis and fluorescent properties of pyrrolo[2,3-*b*]quinoline-3-carboxylates and their benzo[*f*]analogs. *Chem. Heterocyclic Compd.*, 57 1024-1030.
 - 31 Grozav A. N., Kemsyky S.V., Fedoriv M. Z., Chornous V.A., Palamar A.A., Dorokhov V.I., Rusanov E.B., and Vovk M.V. (2022) Synthesis, hydrolysis, and reductive cyclization of ethyl 5-chloro-4-(4-nitropyrrolidin-3-yl)pyrrole-3-carboxylates. *Chem. Heterocyclic Compd.*, 58 24-31.
 - 32 Karpiński T.M., and Szkaradkiewicz A.K. (2015) Chlorhexidine – pharmaco-biological activity and application. *Eur Rev Med Pharmacol Sci.*, 19 (7) 1321-1326.
 - 33 Nazarchuk O.A. (2016) Antiseptics: modern strategy of struggle with causing agents of the infection complications. *Klin. Khir.*, 9 59-61.
 - 34 Mondal P., and Mondal S. (2022) Synthesis, characterization and SAR studies of Novel Series of Spiro β -Lactam of 5-methyl-indole-2,3-dione derivatives as a potential antibacterial and anthelmintic agent *Curr. Chem. Lett.*, 11 403-414.



© 2023 by the authors; licensee Growing Science, Canada. This is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).